Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Art & Psychiatry
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Conference Oration
Conference Summary
Continuing Medical Education
Cosmetic Dermatology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
Editor Speaks
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Miscellaneous Letter
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News & Views
Observation Letter
Observation Letters
Original Article
Original Contributions
Pattern of Skin Diseases
Pediatric Dermatology
Pediatric Rounds
Presedential Address
Presidential Address
Presidents Remarks
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Review Article
Review Articles
Revision Corner
Self Assessment Programme
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Study Letter
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapy Letter
View Point
What’s new in Dermatology
View/Download PDF

Translate this page into:

Net letter
doi: 10.4103/0378-6323.77496
PMID: 21393977

Primary cutaneous CD30+ lymphoproliferative disorder in an atopic dermatitis patient on cyclosporine therapy

S Nakamura1 , K Takeda2 , Y Hashimoto3 , T Mizumoto3 , A Ishida-Yamamoto2 , H Iizuka2
1 Department of Dermatology, Asahikawa Kousei Hospital, Asahikawa;Department of Dermatology, Asahikawa Medical College, Asahikawa, Japan
2 Department of Dermatology, Asahikawa Medical College, Asahikawa, Japan
3 Department of Dermatology, Asahikawa Kousei Hospital, Asahikawa, Japan

Correspondence Address:
S Nakamura
Department of Dermatology, Asahikawa Medical College, Midorigaoka Higashi 2-1-1-1, Asahikawa, 078-8501, Hokkaido
How to cite this article:
Nakamura S, Takeda K, Hashimoto Y, Mizumoto T, Ishida-Yamamoto A, Iizuka H. Primary cutaneous CD30+ lymphoproliferative disorder in an atopic dermatitis patient on cyclosporine therapy. Indian J Dermatol Venereol Leprol 2011;77:253
Copyright: (C)2011 Indian Journal of Dermatology, Venereology, and Leprology


The risk of lymphoma in atopic dermatitis (AD) is controversial, and both positive and negative correlation has been reported. The relation may rather be related to its therapy. Additionally, increment of middle-aged AD might be related. The age of 9.6% of AD in Japan was over 46 years. Recently, beneficial effect of cyclosporine for AD has been established. However, after using cyclosporine for AD, primary cutaneous CD30+ lymphoproliferative disorder (including lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (ALCL), and borderline lesion) is sporadically observed. [1],[2],[3],[4] Recent report indicated that CD30+ T lymphocytes are up-regulated in the lesional skin of AD by mast cells which show the regulatory roles on both innate and acquired immunities. [5]

A 57-years-old man was treated by topical corticosteroid ointment and antihistamine by a local dermatologist because of itchy chronic eruptions under a diagnosis of AD for about 20 years. He had no methotrexate administration or PUVA therapy. It was not clear whether he received steroid administration treatment. Because of the lack of response, he was referred to our hospital [[Figure - 1]a]. Total body analyses including CT and Ga scintigraphy did not disclose any systemic manifestations including mycosis fungoides or cutaneous lymphoma. Histopathology of the skin lesion was consistent with AD [[Figure - 1]b and c].

Figure 1: (a) Lichenified, scaly, erythematous plaques on the back. (b) Histopathological findings. (H and E, 100). Inflammatory infiltrate is observed on the upper dermis. Hyperkeratosis, acanthosis, and parakeratosis. Epidermal spongiosis and lymphoid cell infiltration. (c) CD30+ lymphocytes were scarce

We started pre-prandial administration of cyclosporine (150 mg/twice a day; 2.2 mg/kg/day). The concentration of trough level was 65 ng/ml. The maximum concentration of cyclosporine was got at 1 h and showed 770 ng/ml. Atopic erythema and itching were decreased dramatically. After eight weeks of treatment, exudative erythematous plaque was detected on his right thigh [[Figure - 2]a]. Topical application of betamethasone 17-valerate ointment was not effective and peripheral reddish nodules were developed. Cyclosporine was discontinued and skin biopsy was performed for the tumor [[Figure - 2]b]. Superficial lymph nodes were not palpable. Skin biopsy disclosed dense lymphoid cell infiltrate in the upper dermis [[Figure - 3]a] and anaplastic large cells with bizarre morphology [[Figure - 3]b]. The anaplastic cells were CD3+ and CD30+ [[Figure - 3]c].Anaplastic lymphoma kinase (ALK) 1 protein and EB virus were negative. T cell receptors gene rearrangement of the skin nodule was negative. CT, Ga scintigraphy, MRI, PET-CT, bone marrow aspiration, gastric and colon endoscopies did not detect any systemic manifestations. Peripheral blood analyses disclosed no abnormality, either. Liver function tests, BUN and serum creatinine levels were also normal. Serum soluble interleukin-2 receptor and thymidine kinase activity were 294 U/ml (normal:149-519 U/ml), and 4.8 U/l (<5 U/ml), respectively. Serum IgE was 37.1 IU/ml (0-170I U/ml). Thymus and activation-regulated chemokine (TARC; chemokine of Th2) was 1,455 pg/ml (<450 pg/ml). We diagnosed this case as a CD30+ lymphoproliferative disorder (Type A LyP) by those histological examinations, laboratory examinations, and clinical features. Skin nodules subsided spontaneously without any specific treatment. His AD has been favorably treated by corticosteroid ointment, skin emollients and antihistamine administration.

Figure 2: Clinical presentations on the right thigh. (a) Exudative erythematous plaque was detected. (b) The nodules were still enlarging following the discontinuation of cyclosporine
Figure 3: Histopathological findings. (a) Low magnification (20). Numerous mononuclear cell infiltrates are noted in the upper dermis. (b) Bizarre-shaped cells with conspicuous nucleolus (200). (c) Most of the infiltrated cells were CD30+ (200)

CD30+ lymphoproliferative disorder in AD patients during cyclosporine therapy is rare and only four cases have been described [Table - 1]. [1],[2],[3],[4] Cyclosporine is also used for psoriasis, which is accompanied by similar lymphoproliferative disorder. While some reports suggest no significant relation between AD and lymphoma, others suggest the positive correlation between cutaneous lymphoproliferative disorder and AD. [1] As shown in [Table - 1], CD30+ lymphoproliferative disorder in AD patients treated by cyclosporine, three of the five reported cases showed the LyP type histopathology and four of the five cases showed resolution of the lesion without progression to genuine lymphoma.

Table 1: Cutaneous CD30+ lymphoproliferative disorder in atopic dermatitis treated by cyclosporine

Recent reports indicate that CD30+ T lymphocytes are up regulated in the lesional skin of AD. This is induced by interleukin-8, macrophage inflammatory protein (MIP)-1α, and MIP-1β derived from mast cells. This novel activation pathway does not depend on the classical IgE pathway and this pathway may be observed in psoriasis as well as in Hodgkin lymphoma. [5] Mast cells may have a regulatory role on both innate and acquired immunity. [5] In our case, numerous CD30+ T lymphocytes were detected in skin tumors after cyclosporine administration, which was not apparent in the pre-existing AD lesion. We could not get the samples and not detect the change in the number of mast cells or cytokines derived from mast cells of the skin during the tumor progression and regression in this case. Cyclosporine, besides its well-known immunosuppressive effect, might have changed the cytokine balance including mast cell-derived cytokines.

Our case indicates the potential risk of cutaneous CD30+ lymphoproliferative disorder in cyclosporine-treated AD. Cyclosporine-induced lymphoproliferative disorder, albeit rare, should be kept in mind during the cyclosporine treatment of AD.

Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, Russel-Jones R. CD30+ cutaneous lymphoma in association with atopic eczema. Arch Dermatol 2004;140:449-54.
[Google Scholar]
Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol 2002;47:S165-7.
[Google Scholar]
Laube S, Stephens M, Smith AG, Whittaker SJ, Tan BB. Lymphomatoid papulosis in a patient with atopic eczema on long-term cyclosporine therapy. Br J Dermatol 2005;152:1346-8.
[Google Scholar]
Mougel F, Dalle S, Balme B, Houot R Thomas L. Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis. Dermatology 2006;213:239-41.
[Google Scholar]
Fischer M, Harvima IT, Carvalho RF, Moller C, Naukkarinen A, Enblad G, et al. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Investig 2006;116:2748-56.
[Google Scholar]

Fulltext Views

PDF downloads
Show Sections